Nazli Dizman, MD

GU Oncology Now

<p>Nazli Dizman, MD, an Internal Medicine Resident at Yale University, spoke with us about<a href="https://pubmed.ncbi.nlm.nih.gov/36681606/" target="_blank" rel="noopener"> the recent study that she contributed to</a> on the combination of pembrolizumab and axitinib as a second- and further-line treatment for metastatic renal cell carcinoma.&nbsp; She describes the factors that may contribute to a positive outcome in patients when receiving this combination, along with it&rsquo;s potential to become a standard of care further-line treatment in the future.<p>View Dr. Dizman&rsquo;s other comments on the <a href="https://guoncologynow.com/post/pembrolizumab-plus-axitinib-and-the-future-of-further-line-mrcc-treatments" target="_blank" rel="noopener">future of further-line mRCC treatments.</a></p></p>


Pembrolizumab Plus Axitinib in the Second-line and Beyond for mRCC

Advanced Renal Cell Carcinoma

Dr. Dizman describes the factors that may contribute to positive outcomes in patients receiving pembrolizumab/axitinib as a second- or further-line treatment.

Pembrolizumab Plus Axitinib in the Second-line and Beyond

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe